title: The effect of fiber-rich carbohydrates on features of Syndrome X.
abstract: There has been much debate among nutritionists and scientists regarding the optimal dietary approach for the treatment of the Insulin Resistance Syndrome, also called Syndrome X. This condition, which may affect as many as 47 million individuals in the United States, significantly increases risk of coronary heart disease and stroke. Major health organizations have historically recommended high-carbohydrate, low-fat (HCLF) diets to reduce chronic disease risk. However, there is evidence that a high intake of carbohydrates may adversely affect one or more of the abnormalities associated with this syndrome. Studies in this area have often had limitations. For example, some studies showing adverse effects of an HCLF diet have not taken into account the dietary fiber content of the diet. This article describes abnormalities often associated with Syndrome X, reviews the beneficial effects of fiber-rich carbohydrates, discusses the effect of fiber-rich carbohydrates on features of this syndrome, and concludes with applications of these findings for those involved in treating individuals with features of this disorder. This review indicates that an HCLF dietary pattern such as that used in the DASH trial, with a level of dietary fiber consistent with the recommendations of the American Dietetic Association (eg, 20-35g/day), containing from 3 to 10 g soluble fiber/day, may be beneficial for treating those with Syndrome X.
authors.affiliation: Department of Medicine, The University of Mississippi Medical Center, Jackson 39216, USA.
authors.forename: Brenda M
authors.initials: BM
authors.lastname: Davy
authors.forename: Christopher L
authors.initials: CL
authors.lastname: Melby
mesh_terms: D000005:Abdomen / Q000033:anatomy & histology; D000273:Adipose Tissue / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D004040:Dietary Carbohydrates / Q000008:administration & dosage* / Q000009:adverse effects; D004043:Dietary Fiber / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008074:Lipoproteins / Q000097:blood; D024821:Metabolic Syndrome / Q000178:diet therapy* / Q000209:etiology / Q000517:prevention & control; D009765:Obesity / Q000178:diet therapy / Q000503:physiopathology / Q000517:prevention & control; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D004040:Dietary Carbohydrates; D004043:Dietary Fiber; D008074:Lipoproteins